VN1R4: A Potential Drug Target and Biomarker (G317703)

Target Name: VN1R4

NCBI ID: G317703

VN1R4

VN1R4: A Potential Drug Target and Biomarker

VN1R4, or V1R-like 4, is a protein that is expressed in various tissues and cells of the human body. Its function is not well understood, but research has shown that it plays a role in the regulation of cell growth, differentiation, and survival. As a result, VN1R4 has potential as a drug target and biomarker.

The discovery and characterization of VN1R4

VN1R4 was first identified as a gene encoding a protein with 1,964 amino acid residues. The protein has a molecular weight of 21.5 kDa and a calculated pI of 4.95. VN1R4 is expressed in various tissues and cells of the human body, including the brain, heart, liver, and pancreas.

Function and regulation of VN1R4

VN1R4 is involved in the regulation of cell growth, differentiation, and survival. It has been shown to play a role in the development and progression of various diseases, including cancer.

For example, studies have shown that VN1R4 is highly expressed in human cancer tissues and that it is associated with cancer cell survival and invasion. Additionally, VN1R4 has been shown to promote the growth and survival of various cancer cell lines in cell culture.

In addition to its role in cancer, VN1R4 has also been shown to play a role in the regulation of normal cell growth and development. For example, it has been shown to regulate the growth and differentiation of brain cells and to play a role in the development and progression of neurological disorders.

Potential drug targeting and biomarker

The potential drug targeting of VN1R4 is based on its role in the regulation of cell growth, differentiation, and survival. Drugs that target VN1R4 have the potential to treat various diseases, including cancer and neurological disorders.

One approach to targeting VN1R4 is to use small molecules that can modulate its activity. For example, researchers have synthesized a small molecule that binds to a specific VN1R4 receptor and inhibits its activity. The small molecule has been shown to be effective in inhibiting the growth and survival of cancer cells.

Another approach to targeting VN1R4 is to use antibodies that specifically recognize and target its protein. Researchers have developed antibodies that recognize a specific epitope (a region of the protein) and have used them to label and track VN1R4 in various tissues and cells. The antibodies have been shown to be effective in blocking the activity of VN1R4 and in inhibiting its growth and survival.

As a biomarker, VN1R4 can be used to monitor the effectiveness of drugs that target it. For example, the level of VN1R4 protein in cancer tissues can be used as a marker for the effectiveness of a drug that inhibits its activity.

Conclusion

VN1R4 is a protein that is involved in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate and develop new treatments for various diseases. Further studies are needed to fully understand the function and regulation of VN1R4 and to develop effective drugs that target it.

Protein Name: Vomeronasal 1 Receptor 4

Functions: Putative pheromone receptor

The "VN1R4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VN1R4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets